"WAYFIND-R enables the generation of real-world evidence, not possible with classical clinical trials, including: natural history of novel subtypes, outcomes of patients not included in trials, impact of subsequent lines and information on outliers. This is an essential corpus of knowledge, which needs to be brought to the attention of all physicians, clinicians and researchers."

Professor Jean-Yves Blay has been Director of the Centre Léon Bérard, the comprehensive cancer centre of Lyon and the Rhône-Alpes region, since December 2014. He is also a medical oncologist professor at the University Claude Bernard Lyon, and was President of the European Organization for Research and Treatment of Cancer (EORTC) from 2009 to 2012. Currently President of the French Sarcoma Group/GETO, he is the network leader of the NETSARC network of reference centres for sarcoma treatment certified by the French National Cancer Institute. He is the director of the Integrated Centre for innovation on Cancer Research of Lyon (LYRIC). Professor Blay is the director of the ERN-EURACAN, designated in December 2016 by the European Commission, to improve the quality of care for patients with rare cancers in the European Union.

He advises on various national and international institutions and research organisations and is an active member of several oncology scientific organisations and societies, including ESMO, ASCO and AACR.

His research interests focus on clinical and basic research in sarcomas, targeted treatment of cancer, the biology of breast carcinoma and the relationship between tumour immunologic microenvironment and malignant cells with the goal of clinical applications in the fields of diagnosis, prognosis, and treatment. He has authored 800+ peer-reviewed articles and his work has been distinguished by several awards, including from the National Academy of Medicine (2013) and from the San Salvatore Foundation, Switzerland (2020).

LINK: https://www.centreleonberard.fr/en/directory/blay-jean-yves